PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048) Meeting Abstract
| Authors: | Schrag, D.; Shi, Q.; Weiser, M. R.; Gollub, M. J.; Saltz, L. B.; Musher, B. L.; Goldberg, J.; Al Baghdadi, T.; Goodman, K. A.; McWilliams, R. R.; Farma, J. M.; George, T. J.; Kennecke, H. F.; Venook, A. P.; O'Reilly, E. M.; Meyerhardt, J. A.; Dueck, A. C.; Basch, E.; Chang, G. J.; Mamon, H. J.; Alliance for Clinical Trials in Oncology |
| Abstract Title: | PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-10 |
| Language: | English |
| ACCESSION: | WOS:001043181100003 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2023.41.17_suppl.LBA2 |
| Notes: | Meeting Abstract: LBA2 -- Meeting also available remotely -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work